Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia
Clinical trial NCT07169565 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07169565
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-09-01
- Primary completion
- 2028-09-01
- Enrollment
- 21
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.